Fredrik Hellem Schjesvold

Image of Fredrik Hellem Schjesvold
Norwegian version of this page
Mobile phone +47-99697796
Username
Visiting address Oslo myelomatosesenter Bygg 20 3.etasje
Postal address Postboks 4950 Nydalen OUS, Rikshospitalet 0424 Oslo

Publications

  • Schjesvold, Fredrik Hellem & Oriol, Albert (2021). Current and novel alkylators in multiple myeloma. Cancers. ISSN 2072-6694. 13(10). doi: 10.3390/cancers13102465.
  • Richardson, Paul G; Harrison, Simon J; Bringhen, Sara; Schjesvold, Fredrik Hellem; Yong, Kwee & Campana, Frank [Show all 9 contributors for this article] (2021). Isatuximab for relapsed/refractory multiple myeloma: Review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncology. ISSN 1479-6694. 17(34), p. 4797–4812. doi: 10.2217/fon-2021-0568.
  • Ludwig, Heinz; Sonneveld, Pieter; Facon, Thierry; San-Miguel, Jesus; Avet-Loiseau, Hervé & Mohty, Mohamad [Show all 36 contributors for this article] (2021). COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. The Lancet Haematology. ISSN 2352-3026. 8(12), p. e934–e946. doi: 10.1016/S2352-3026%2821%2900278-7.
  • Terpos, Evangelos; Zamagni, Elena; Lentzsch, Suzanne; Drake, Matthew; García-Sanz, Ramón & Abildgaard, Niels [Show all 19 contributors for this article] (2021). Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. The Lancet Oncology. ISSN 1470-2045. 22(3), p. e119–e130. doi: 10.1016/S1470-2045%2820%2930559-3.
  • Dimopoulos, Meletios A.; Moreau, Philippe; Terpos, Evangelos; Mateos, Maria-Victoria; Zweegman, Sonja & Cook, G. [Show all 17 contributors for this article] (2021). Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology. ISSN 0923-7534. 32(3), p. 309–322. doi: 10.1016/j.annonc.2020.11.014.
  • Moreau, Philippe; Kumar, Shaji; San Miguel, Jesús; Davies, Faith E.; Zamagni, Elena & Bahlis, Nizar [Show all 70 contributors for this article] (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet Oncology. ISSN 1470-2045. 22(3), p. e105–e118. doi: 10.1016/S1470-2045%2820%2930756-7.
  • Oriol, Albert; Larocca, Alessandra; Leleu, Xavier; Hajek, Roman; Hassoun, Hani & Rodriguez-Otero, Paula [Show all 10 contributors for this article] (2020). Melflufen for relapsed and refractory multiple myeloma. Expert Opinion on Investigational Drugs. ISSN 1354-3784. 29(10), p. 1069–1078. doi: 10.1080/13543784.2020.1808884. Full text in Research Archive
  • Laubach, Jacob P.; Schjesvold, Fredrik H; Mariz, Mário; Dimopoulos, Meletios A.; Lech-Maranda, Ewa & Spicka, Ivan [Show all 26 contributors for this article] (2020). Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. The Lancet Oncology. ISSN 1470-2045. 22(1), p. 142–154. doi: 10.1016/S1470-2045%2820%2930680-X.
  • Schjesvold, Fredrik H; Goldschmidt, Hartmut; Maisnar, Vladimir; Spicka, Ivan; Abildgaard, Niels & Rowlings, Philip [Show all 13 contributors for this article] (2020). Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial. European Journal of Haematology. ISSN 0902-4441. 104(5), p. 443–458. doi: 10.1111/ejh.13379. Full text in Research Archive
  • Kaiser, Martin; Beksac, Meral; Gulbrandsen, Nina; Schjesvold, Fredrik H; Hájek, Roman & Moreau, Philippe [Show all 17 contributors for this article] (2020). Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology. ISSN 0939-5555. 99(8), p. 1793–1804. doi: 10.1007/s00277-020-04149-5. Full text in Research Archive
  • Kaufman, Jonathan L.; Gasparetto, Cristina; Schjesvold, Fredrik H; Moreau, Philippe; Touzeau, Cyrille & Facon, Thierry [Show all 21 contributors for this article] (2020). Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. American Journal of Hematology. ISSN 0361-8609. doi: 10.1002/ajh.26083. Full text in Research Archive
  • Schjesvold, Fredrik H; Robak, Pawel; Pour, Ludek; Aschan, Johan & Sonneveld, Pieter (2020). OCEAN: A randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. Future Oncology. ISSN 1479-6694. 16(11), p. 631–641. doi: 10.2217/fon-2020-0024. Full text in Research Archive
  • Zweegman, Sonja; Claudia A M Stege, A; Haukås, Einar; Schjesvold, Fredrik H; Mark-David Levin, Levin & Waage, Anders [Show all 26 contributors for this article] (2020). Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. ISSN 0390-6078. 105(12), p. 2879–2882. doi: 10.3324/haematol.2019.240374. Full text in Research Archive
  • Schjesvold, Fredrik H (2020). Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. European Journal of Haematology. ISSN 0902-4441. 105(4), p. 434–448. doi: 10.1111/ejh.13464. Full text in Research Archive
  • Attal, Michel; Richardson, Paul G.; Rajkumar, S. Vincent; San-Miguel, Jesús; Beksač, Meral & Špička, Ivan [Show all 20 contributors for this article] (2019). Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. The Lancet. ISSN 0140-6736. 394(10214), p. 2096–2107. doi: 10.1016/S0140-6736%2819%2932556-5.
  • Usmani, Saad Zafar; Schjesvold, Fredrik Hellem; Oriol, Albert; Karlin, Lionel; Cavo, Michele & Rifkin, Robert M. [Show all 22 contributors for this article] (2019). Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. The Lancet Haematology. ISSN 2352-3026. 6(9), p. e448–e458. doi: 10.1016/S2352-3026%2819%2930109-7. Full text in Research Archive
  • Mateos, Maria-Victoria; Blacklock, Hilary; Schjesvold, Fredrik Hellem; Oriol, Albert; Simpson, David & George, Anupkumar [Show all 26 contributors for this article] (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. The Lancet Haematology. ISSN 2352-3026. 6(9), p. e459–e469. doi: 10.1016/S2352-3026%2819%2930110-3. Full text in Research Archive
  • Richardson, Paul G.; Oriol, Albert; Beksac, Meral; Liberati, Anna Marina; Galli, Monica & Schjesvold, Fredrik Hellem [Show all 25 contributors for this article] (2019). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. The Lancet Oncology. ISSN 1470-2045. 20(6), p. 781–794. doi: 10.1016/S1470-2045%2819%2930152-4.
  • Hillengass, Jens; Usmani, Saad; Rajkumar, S. Vincent; Durie, Brian G.M.; Mateos, María-Victoria & Lonial, Sagar [Show all 35 contributors for this article] (2019). International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology. ISSN 1470-2045. 20(6), p. e302–e312. doi: 10.1016/S1470-2045%2819%2930309-2. Full text in Research Archive
  • Dimopoulos, Meletios A.; Gay, Francesca; Schjesvold, Fredrik Hellem; Beksac, Meral; Hájek, Roman & Weisel, Katja Christina [Show all 26 contributors for this article] (2018). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. ISSN 0140-6736. 393(10168), p. 253–264. doi: 10.1016/S0140-6736%2818%2933003-4. Full text in Research Archive
  • Tangen, Jon-Magnus; Tjønnfjord, Geir Erland; Gulbrandsen, Nina; Gedde-Dahl, Thobias; Stormorken, Espen & Anderson, Kristina [Show all 9 contributors for this article] (2018). Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: A retrospective, population based analysis. BMC Cancer. ISSN 1471-2407. 18:801, p. 1–9. doi: 10.1186/s12885-018-4722-x. Full text in Research Archive
  • Wang, Dong; Fløisand, Yngvar; Myklebust, Camilla Victoria; Bürgler, Simone; Ribes, Anna Maria Parente & Hofgaard, Peter Olaf [Show all 13 contributors for this article] (2017). Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia. ISSN 0887-6924. 31(10), p. 2114–2121. doi: 10.1038/leu.2017.69. Full text in Research Archive
  • Torfoss, Dag; Fladhagen, Tone; Holte, Harald; Brinch, Lorentz; Schjesvold, Fredrik Hellem & Fløisand, Yngvar [Show all 15 contributors for this article] (2016). Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial. Clinical Microbiology and Infection (CMI). ISSN 1198-743X. 23(3), p. 179–187. doi: 10.1016/j.cmi.2016.10.019.
  • Tveita, Anders; Schjesvold, Fredrik Hellem; Haabeth, Ole Audun; Fauskanger, Marte Hotvedt & Bogen, Bjarne (2015). Tumors escape CD4+ T-cell-mediated immunosurveillance by impairing the ability of infiltrating macrophages to indirectly present tumor antigens. Cancer Research. ISSN 0008-5472. 75(16), p. 3268–3278. doi: 10.1158/0008-5472.CAN-14-3640.
  • Tveita, Anders; Schjesvold, Fredrik Hellem; Sundnes, Olav; Haabeth, Ole Audun; Haraldsen, Guttorm & Bogen, Bjarne (2014). Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatiallyrestricted and fails to prevent escape of antigen-negative cells. European Journal of Immunology. ISSN 0014-2980. 44(9), p. 2625–2637. doi: 10.1002/eji.201444659.
  • Haabeth, Ole Audun; Tveita, Anders; Fauskanger, Marte Hotvedt; Schjesvold, Fredrik Hellem; Lorvik, Kristina Berg & Hofgaard, Peter Olaf [Show all 11 contributors for this article] (2014). How do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Frontiers in Immunology. ISSN 1664-3224. 5:174. doi: 10.3389/fimmu.2014.00174. Full text in Research Archive

View all works in Cristin

  • Schjesvold, Fredrik Hellem; Tveita, Anders; Sundnes, Olav; Haraldsen, Guttorm & Bogen, Bjarne (2013). CD4+T cell-mediated protection against tumors: no bystander killing. Journal of Immunology. ISSN 0022-1767. 190.
  • Tveita, Anders; Schjesvold, Fredrik Hellem; Haabeth, Ole Audun & Bogen, Bjarne (2013). Escape of myeloma cells from CD4 T-cell-driven immunoprotection. Journal of Immunology. ISSN 0022-1767. 190.
  • Schjesvold, Fredrik Hellem (2009). Erytrocytose til besvær. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 129(22).

View all works in Cristin

Published June 23, 2020 1:15 PM - Last modified Nov. 20, 2020 9:44 AM